CD8A and neoplasm: As expected, contrarily to HER2CAR−NKp30−CD8+ T cells, HER2CAR−NKp30+CD8+ T cells could kill target tumor cells, indicative of the additional NK-like killing capacity of this population (Figure 5(c)).